A compound represented by the general formula (V) ##STR00001##
wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P.sub.5 receptor relative to the S1P.sub.1 receptor, and can thus serve as a therapeutic agent for S1P.sub.5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

A compound represented by the general formula (V) ##STR00001##
wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P.sub.5 receptor relative to the S1P.sub.1 receptor, and can thus serve as a therapeutic agent for S1P.sub.5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

Provided are synthesis processes and intermediates for preparing cannabinoids and analogs.

Provided are synthesis processes and intermediates for preparing cannabinoids and analogs.

A compound represented by the general formula (V)

##STR00001##

wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P.sub.5 receptor relative to the S1P.sub.1 receptor, and can thus serve as a therapeutic agent for S1P.sub.5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

A compound represented by the general formula (V)

##STR00001##

wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P.sub.5 receptor relative to the S1P.sub.1 receptor, and can thus serve as a therapeutic agent for S1P.sub.5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

This disclosure is related to methods for producing anhydroryanodol, ryanodol, or analogues thereof and novel compounds prepared thereby.

This disclosure is related to methods for producing anhydroryanodol, ryanodol, or analogues thereof and novel compounds prepared thereby.

Provided are a liquid crystal compound satisfying at least one of physical properties such as high stability to heat or light, a high clearing point (or high maximum temperature), low minimum temperature of a liquid crystal phase, small viscosity, large optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and good compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition.

A compound is represented by formula (1):

##STR00001##

wherein, R.sup.1 and R.sup.2 are alkyl having 1 to 15 carbons; A.sup.1, A.sup.2, A.sup.3 and A.sup.4 are 1,4-cyclohexylene and 1,4-phenylene; Z.sup.1, Z.sup.2, Z.sup.3 and Z.sup.4 are a single bond; Y.sup.1, Y.sup.2 and Y.sup.3 are fluorine; and a, b, c and d are 0 or 1, and a sum of a, b, c and d is an integer from 0 to 3, or the like.

Provided are a liquid crystal compound satisfying at least one of physical properties such as high stability to heat or light, a high clearing point (or high maximum temperature), low minimum temperature of a liquid crystal phase, small viscosity, large optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and good compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition.

A compound is represented by formula (1):

##STR00001##

wherein, R.sup.1 and R.sup.2 are alkyl having 1 to 15 carbons; A.sup.1, A.sup.2, A.sup.3 and A.sup.4 are 1,4-cyclohexylene and 1,4-phenylene; Z.sup.1, Z.sup.2, Z.sup.3 and Z.sup.4 are a single bond; Y.sup.1, Y.sup.2 and Y.sup.3 are fluorine; and a, b, c and d are 0 or 1, and a sum of a, b, c and d is an integer from 0 to 3, or the like.